USANA Health Sciences Inc. said its normalized net income for the fiscal fourth quarter ended Jan. 2 came to 85 cents per share, compared with the S&P Capital IQ consensus estimate of 100 cents per share.

EPS increased 9.5% year over year from 78 cents.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was $22.2 million, an increase of 10.8% from $20.0 million in the prior-year period.

The normalized profit margin climbed to 9.6% from 8.8% in the year-earlier period.

Total revenue grew on an annual basis to $232.6 million from $227.9 million, and total operating expenses climbed year over year to $197.4 million from $195.2 million.

Reported net income rose 12.1% from the prior-year period to $23.9 million, or 92 cents per share, from $21.4 million, or 82 cents per share.

For the year, the company's normalized net income totaled $3.38 per share, compared with the S&P Capital IQ consensus normalized EPS estimate of $3.67.

EPS rose 28.1% from $2.64 in the prior year.

Normalized net income was $89.1 million, an increase of 23.3% from $72.3 million in the prior year.

Full-year total revenue increased 16.2% on an annual basis to $918.5 million from $790.5 million, and total operating expenses grew 15.2% year over year to $776.8 million from $674.4 million.

The company said reported net income increased 23.4% on an annual basis to $94.6 million, or $3.59 per share, in the full year, from $76.7 million, or $2.80 per share.